53.00 -0.72 (-1.34%)
After hours: 5:02PM EDT
Commodity Channel Index
|Bid||53.66 x 800|
|Ask||53.51 x 1100|
|Day's Range||51.40 - 53.73|
|52 Week Range||21.56 - 58.72|
|Beta (5Y Monthly)||1.80|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 29, 2020 - Aug 03, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||61.47|
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of March 31st, a week after the market trough. Now, we are […]
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you buy shares in a...
If you are looking for the best ideas for your portfolio you may want to consider some of Mott Capital's top stock picks. Mott Capital, an investment management firm, is bullish on Acadia Pharmaceuticals Inc (NASDAQ:ACAD) stock. In its Q4 2019 investor letter – you can download a copy here – the firm discussed its […]
For those that thought the extreme market volatility was behind us, think again. Last week, another burst of volatility was brought on by concerns about the U.S. economic recovery and a second wave of COVID-19. This week, however, U.S. stocks recovered some lost ground thanks to strong retail sales data. There's a lot going on in the markets, and the only certainty is uncertainty.Against this backdrop, we turned our attention to defensive stocks in the healthcare sector. In general, these stocks provide stable earnings regardless of the stock market’s state due to the constant demand for their products or services.With this in mind, we used TipRanks’ database to identify three defensive healthcare stocks with upside potential north of 20%. Not to mention each of these companies has earned a “Strong Buy” consensus rating from the analyst community.Deciphera Pharmaceuticals (DCPH)We will start with Deciphera, a biopharmaceutical company which develops cancer medications. On May 15, the company received FDA approval for its QINLOCK™ therapy. The drug is used for the treatment of fourth-line gastrointestinal stromal tumor (GIST), a type of tumor that originates in the gastrointestinal tract.The good news didn’t end there. On June 8, Deciphera announced that The Lancet Oncology (a medical journal) published positive results from the INVICTUS Phase 3 study of QINLOCK, which featured patients who have been previously treated with anticancer therapies. Data from the study showed a statistically significant improvement in the progression free survival in patients randomized to QINLOCK, compared with patients receiving a placebo.5-star analyst Christopher Raymond, of Piper Sandler, expressed enthusiasm for QINLOCK. Soon after the company received the FDA’s stamp of approval, the analyst said he expects “meaningful upside in coming months as the setup for the launch of QINLOCK remains quite positive.”As a result, Raymond rates DCPH an Outperform (i.e. Buy). The analyst believes the stock has more room to run, as he maintains a $75 price target. This implies upside potential of 21% from current levels. (To watch Raymond’s track record, click here)Like Raymond, other analysts are also bullish on the stock. The 11 ratings on the stock include 9 Buys, only 2 Holds and no Sells, adding up to a Strong Buy consensus rating. The average price target of $71.20 represents a possible 15% increase from the share price of $59.50. (See Deciphera stock analysis on TipRanks)Laboratory Corporation of America (LH)Up next is Laboratory Corporation of America, which operates two divisions, LabCorp Diagnostics (LCD) and Covance Drug Development. LCD provides clinical laboratory services such as blood, urine, and COVID-19 tests, while Covance offers services that help clients manage the drug development process.The company’s sales were only slightly affected by the COVID-19 pandemic. Revenue for the first quarter of 2020 was $2.8 billion, an increase of 1.2% from the prior-year quarter. The increase in revenue was due to acquisitions, partially offset by the negative impact from COVID-19. However, earnings took a bigger hit thanks to the public health crisis, as the operating loss for the quarter was $193 million, compared to operating income of $318 million in the first quarter of 2019.J.P. Morgan analyst Lisa Gill believes Laboratory is better positioned than the competition because of its income diversity, with it also less exposed to upcoming Medicare cuts. To provide additional support for her bullish thesis, the 5-star analyst cites improving trends in the company’s core business.To this end, Gill rates LH an Overweight (i.e. Buy), while raising her price target from $118 to $223. The new figure implies upside potential of 31% from current levels. (To watch Gill’s track record, click here)Turning now to the rest of the Street, most other analysts are on the same page. Laboratory has a Strong Buy analyst consensus rating comprised of 10 Buys, 3 Holds and no Sell ratings. The average price target on the stock is $213.27, which suggests 25% upside potential. (See LH stock analysis on TipRanks)ACADIA Pharmaceuticals (ACAD)Last on our list is ACADIA, a biopharmaceutical company that designs medications for central nervous system disorders. ACADIA has developed the only approved therapy for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis, NUPLAZID.Despite COVID-19, sales of NUPLAZID increased 43% to reach $90.1 million for the three months ended March 31, 2020, compared to $63 million in the first quarter of 2019. In addition, management announced it completed a pre-sNDA meeting (a meeting between a company and the FDA to ensure the submission of a well-organized NDA), and is on-track to submit a supplemental NDA this summer for NUPLAZID as a potential breakthrough therapy for DRP (drug related problems) and MDD (major depressive disorder).5-star analyst Charles Duncan, representing Cantor Fitzgerald, viewed management’s announcement positively. In a recent research note, he cited the company’s positive outlook as a major component of his bullish thesis. “Pipeline driven potential is more than additive to our view that NUPLAZID is continuing to gain traction on volume growth by increasing penetration and persistence,” he stated.To this end, Duncan has an Overweight (i.e. Buy) rating on the stock. Along with his rating, the analyst gave the price target a lift, from $58 to $63, implying 34% upside potential. (To watch Duncan’s track record, click here).Other analysts on the Street agree with Duncan and also have high expectations for the stock, with 9 Buys and 1 Hold resulting in a Strong Buy consensus rating. The average price target is $60.30, which implies upside potential of 27%. (See ACADIA stock-price forecast on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
ACADIA (ACAD) files an sNDA for Nuplazid's potential second indication to treat hallucinations and delusions linked to dementia-related psychosis.
Acadia Pharmaceuticals Inc. (ACAD) has announced that it has filed a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to support a potential new indication for Nuplazid (pimavanserin) for the treatment of hallucinations and delusions associated with dementia-related psychosis (DRP).The FDA previously granted Breakthrough Therapy Designation for pimavanserin for this indication.“This is an important step forward for the approximately 2.4 million people in the U.S. who suffer from dementia-related hallucinations and delusions, representing a large unmet need with currently no approved treatment options,” said Steve Davis, Acadia’s CEO.The application follows ACAD’s pivotal Phase 3 HARMONY study, which met its primary endpoint, demonstrating that pimavanserin significantly reduced the risk of relapse of psychosis by 2.8 fold compared to placebo.The sNDA also includes positive efficacy results from two additional placebo-controlled studies, both of which met their respective primary endpoints, and a large safety and tolerability database of over 1500 patients.Dementia affects approximately 8 million people in the U.S, with roughly 30% experiencing dementia-related psychosis. Only half, or 1.2 million, are diagnosed and treated.Nuplazid was approved in the U.S. in 2016 as the first and only treatment for hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). And looking forward, Acadia is also investigating pimavanserin as a treatment for the negative symptoms of schizophrenia and major depressive disorder (MDD).Following the news RBC Capital’s Gregory Renza reiterated his ACAD buy rating with a $58 price target (25% upside potential).“With the Breakthrough Therapy Designation of pimavanserin in DRP, we believe the application could receive priority review and therefore expect approval around year-end… which would not surprise given pim’s position as the first treatment option in DRP” he explained.The analyst is modelling U.S. peak sales of Nuplazid reaching $2.4B in PDP and DRP, writing “[we] expect a 90% likelihood of approval in DRP which is a significant contributor to out-year revenues and drives over 40% of our valuation.”He also recommends keeping an eye out for the MDD readout from the combined CLARITY 2/3 trials, which is expected in 3Q. “If successful, we believe the label expansion potential could bring additional upside to the company” says Renza, who sees $1.5B U.S. peak sales opportunities in MDD with a 50% probability of success.Overall, ACAD scores a Strong Buy Street consensus with 9 buy ratings and 1 hold. The average analyst price target stands at $60 (30% upside potential). Shares are currently trading up 9% year-to-date. (See ACAD stock analysis on TipRanks)Related News: Medtronic Succeeds In Critical US Trial For New Insulin Pump Jazz Pharma Scores Surprise Early Approval For Lung Cancer Treatment Merck’s Gardasil Receives FDA Nod For Expanded Cancer Indications More recent articles from Smarter Analyst: * AstraZeneca Strikes $127 Million Deal With Brazil For Covid-19 Vaccine * American Airlines: Equity Raise Reduces Bankruptcy Fears * Nintendo To Reduce Mobile Gaming Presence, Wedbush Downgrades Stock * Insiders Sell $596M Of DraftKings Stock, Taking Advantage of 230% Rally
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that the company submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to support a potential new indication for NUPLAZID® (pimavanserin) for the treatment of hallucinations and delusions associated with dementia-related psychosis (DRP). The FDA previously granted Breakthrough Therapy Designation for pimavanserin for the treatment of hallucinations and delusions associated with DRP.
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each […]
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the Goldman Sachs 41st Annual Global Healthcare Conference on Tuesday, June 9, 2020, at 4:40 p.m. Eastern Time.
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today announced that Mark Schneyer has been appointed to the newly created position of Senior Vice President, Business Development and Chief Business Officer. Mr. Schneyer will be responsible for sourcing and executing business development opportunities and serve as a member of the company’s Executive Management Committee. He will report to Steve Davis, Chief Executive Officer.
ACADIA (ACAD) to club two late-stage studies on Nuplazid into a single evaluation program for the adjunctive treatment of MDD. Top-line results from the same are expected in Q3.
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that following positive feedback from the U.S. Food and Drug Administration the company plans to combine its CLARITY-2 and CLARITY-3 Phase 3 studies evaluating pimavanserin for the adjunctive treatment of major depressive disorder (MDD) into one study with a pre-specified statistical analysis plan. As a result, no new patients will be enrolled in the two identically designed Phase 3 studies, each of which will be concluded with slightly more than 50% enrollment. Top-line results from the combined study are expected in the third quarter of 2020.
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that multiple scientific presentations and abstracts evaluating pimavanserin in clinical studies for the treatment of various central nervous system (CNS) disorders will be highlighted at the 2020 American Society of Clinical Psychopharmacology (ASCP) Virtual Annual Meeting on May 29-30, 2020.
It's been a pretty great week for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shareholders, with its shares surging 13...
ACADIA's (ACAD) earnings and sales lag estimates in the first quarter of 2020. The company trims its 2020 revenue guidance due to the coronavirus impact. Stock declines in after-hours trading.
Acadia (ACAD) delivered earnings and revenue surprises of -23.91% and -3.36%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its financial results for the quarter ended March 31, 2020.
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) and Vanderbilt University today announced an exclusive worldwide license agreement to develop and commercialize novel drug candidates targeting the muscarinic M1 receptor with the potential to treat a range of central nervous system (CNS) disorders. The collaboration will focus on positive allosteric modulators (PAMs) of the M1 receptor.
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the following two investor conferences:
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Thursday, May 7, 2020, after the close of the U.S. financial markets. ACADIA’s management team will also host a conference call and webcast on Thursday, May 7, 2020, at 4:30 p.m. Eastern Time to discuss financial results and operations.